Mode
Text Size
Log in / Sign up

Aneurysm location does not significantly affect mortality or functional outcomes in aneurysmal subarachnoid hemorrhageLocation Doesn't Rule Out Recovery After Brain Bleed

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that aneurysm location alone should not guide prognostic decisions or limit aggressive treatment in aSAH.

This systematic review and meta-analysis pooled data from 2,611 patients with aneurysmal subarachnoid hemorrhage (aSAH), comprising 1,625 with anterior circulation and 986 with posterior circulation aneurysms. The study compared outcomes between these two anatomical subgroups to determine if location influenced prognosis. The primary outcome was mortality, with secondary outcomes including functional recovery, hydrocephalus, delayed cerebral ischemia (DCI), and symptomatic cerebral vasospasm. Follow-up for functional outcomes occurred at 6 months and 1 year.

Regarding mortality, no significant difference was observed between anterior and posterior circulation groups, with a pooled rate of 13% (95% CI: 10%-17%; p = 0.437). Functional outcomes were also comparable, with 60% (95% CI: 51%-67%) achieving good recovery at 6 months and 55% (95% CI: 46%-64%) at 1 year. Rates of hydrocephalus were identical at 35% for both groups (p = 0.979), and DCI occurred in 17% of patients regardless of location (p = 0.939). However, symptomatic cerebral vasospasm was significantly more frequent in the anterior circulation group (24%) compared to the posterior group (11%; p = 0.018).

Safety data, adverse events, and tolerability were not reported. A key limitation is the high heterogeneity for mortality (I² = 84.6%), suggesting variability in study populations or methodologies. The authors note that admission neurological grade (WFNS) appears to be the primary determinant of mortality rather than aneurysm location. As this is a meta-analysis of observational studies, causal inferences are limited. Consequently, aneurysm location alone should not guide prognostic decisions or limit aggressive treatment strategies.

Imagine waking up in a hospital after a sudden, terrifying brain bleed. Doctors tell you the news is grim because the tear happened in the back part of your brain. You might feel a heavy weight on your chest, thinking your chances are gone.

But new research changes that story.

A brain bleed called aneurysmal subarachnoid hemorrhage (aSAH) is a scary event. It happens when a weak spot in a blood vessel bursts. This causes blood to leak into the space around the brain.

This condition is dangerous. It can lead to death or long-term disability. Many people worry that bleeds in the back part of the brain are always worse. Doctors have long believed this because of the complex anatomy and severe bleeding often seen there.

However, patients deserve hope based on facts, not just old beliefs.

The Surprising Shift

For years, medical experts assumed the location of the tear was the most important factor. They thought back-of-the-brain bleeds meant a poorer outcome than front-of-the-brain ones.

But here's the twist. A massive new review of data shows this isn't true. When scientists looked at thousands of cases, they found the location didn't matter as much as we thought.

Think of your brain like a busy city. Blood vessels are the roads. An aneurysm is a pothole that suddenly explodes.

The old idea was that a pothole in the back district caused more traffic jams than one in the front. The new data says the size of the explosion and the initial shock to the brain matter more than the district it happened in.

Researchers looked at studies published between 2000 and 2025. They gathered information on over 2,600 patients.

They compared those with bleeds in the front circulation against those with bleeds in the back circulation. They tracked who died, who recovered well, and who faced complications like fluid buildup in the brain.

The results were clear. The chance of dying was about the same for both groups. Roughly 13% of all patients died, regardless of where the bleed occurred.

Recovery rates were also similar. About 60% of patients had a good recovery six months later. This number didn't change based on the location of the aneurysm.

There was one specific difference. Patients with front-of-the-brain bleeds were slightly more likely to develop a specific type of brain swelling called symptomatic cerebral vasospasm. This happened in 24% of front cases versus 11% of back cases.

But there's a catch.

This difference is important for doctors to watch, but it doesn't change the overall picture of survival or major recovery.

The main driver of survival is how the patient looks when they arrive at the hospital. Doctors use a scale called WFNS to grade this.

If a patient is confused or weak upon arrival, the outlook is harder. If they are alert and calm, the outlook is better. The location of the tear is secondary to this initial state.

This news is practical. It means doctors should not limit treatment options just because a bleed is in the back of the brain.

Patients and families can stop fearing the location alone. The focus should be on the patient's current condition and getting aggressive, appropriate care.

This study combined data from many sources. While the numbers are large, each individual study had its own small group of patients.

Also, this is a review of past data. It tells us what has happened, not exactly what will happen to every single person.

This research helps guide better care today. It suggests that prognostic decisions should rely on the patient's admission grade, not just the aneurysm's spot.

Future trials will likely focus on treating the specific complications like vasospasm more effectively. Until then, the message is clear: location does not define your future.

Study Details

Study typeMeta analysis
Sample sizen = 1,625
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
Background: Aneurysmal subarachnoid hemorrhage (aSAH) is a severe form of stroke associated with higher morbidity and mortality. Posterior circulation aneurysms are considered to have worse prognosis than anterior circulation aneurysms due to anatomical location, hemorrhage severity, and treatment complexity. We aimed to determine whether aneurysm location independently influences clinical outcomes following aSAH Methods: PubMed, Scopus, Embase, and Web of Science were searched from January 2000 to December 2025 for studies reporting outcomes in anterior or posterior circulation aSAH. The outcome analysis included mortality, functional recovery (modified Rankin Scale [mRS] 0-2 and 3-6 at 6 months and 1 year), hydrocephalus, delayed cerebral ischemia (DCI), and symptomatic cerebral vasospasm. Pooled proportions and subgroup comparisons were performed using random-effects meta-analysis (DerSimonian-Laird method). Publication bias was evaluated using contour-enhanced funnel plots and Egger's test. Results: Nineteen analytic entries from 18 studies (anterior: n = 1,625; posterior: n = 986; total N = 2,611) were included. Pooled mortality was 13% (95% CI: 10%-17%; I2 = 84.6%), with no significant difference between the anterior (14%; 95% CI: 10%-20%) and posterior (11%; 95% CI: 7%-18%) circulation subgroups (p = 0.437). Good functional outcome was 60% at 6 months (95% CI: 51%-67%) and 55% at 1 year (95% CI: 46%-64%), with no location-based differences. Hydrocephalus (35% vs 35%; p = 0.979) and DCI (17% vs 17%; p = 0.939) were comparable between subgroups. Symptomatic cerebral vasospasm was the only outcome differing significantly by location, occurring more frequently in anterior circulation aSAH (24% vs 11%; {chi}2 = 5.59; p = 0.018). Conclusion: Aneurysm location does not independently determine mortality, functional recovery, hydrocephalus, or DCI following aSAH. Symptomatic cerebral vasospasm was the only location-specific outcome. Admission neurological grade (World Federation of Neurosurgical Societies [WFNS]), rather than vascular territory, appears to be the primary determinant of mortality. Aneurysm location alone should not guide prognostic decisions or limit aggressive treatment.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.